Skip to content
PeptideFactSheets
In clinical trialsEarly human evidence

Plain-English fact sheet

Retatrutide

Also known as LY3437943

Retatrutide is an investigational peptide-based medicine being studied in large trials; it is not FDA approved.

Quick answer

Retatrutide activates GIP, GLP-1, and glucagon receptors and is being studied in Phase 3 programs. It is not an FDA-approved medicine.

By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.

What is Retatrutide?

Retatrutide is a manufactured peptide designed to activate three metabolic signaling receptors.

It remains a research drug. Registered trials are testing both benefits and risks in defined populations.

Why are people interested in it?

Early human studies reported substantial average weight changes, which generated strong public interest.

Phase 3 trials are intended to test whether those results hold up in larger, more diverse groups and to characterize safety more completely.

Current regulatory status

In clinical trials

Retatrutide is not FDA approved. Multiple Phase 3 and Phase 3b studies are registered, including trials for obesity and related outcomes.

What is it approved for?

No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.

What is it being studied for?

Obesity and overweight
Type 2 diabetes
Cardiovascular and kidney outcomes
Obstructive sleep apnea
Knee osteoarthritis in people with obesity or overweight

Investigational areas

  • Body-weight reduction and maintenance
  • Metabolic and cardiovascular outcomes
  • Obesity-related conditions

Evidence snapshot

Early human evidence

Published human trials provide an early signal, but the overall evidence base is less mature than for approved medicines and pivotal trials remain ongoing.

Potential benefits being researched

  • Earlier trials observed changes in body weight and metabolic measures.
  • Ongoing Phase 3 trials are designed to provide more reliable estimates of benefits and harms.

Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.

Known or possible risks

  • Earlier trials reported gastrointestinal adverse effects, among other events.
  • A research program may identify uncommon or longer-term risks only after larger and longer studies.
  • Products marketed online as retatrutide are not an FDA-approved version of the investigational drug.

What we still do not know

  • Whether Phase 3 trials will confirm earlier efficacy findings
  • The complete adverse-effect profile across larger populations
  • Which indications, populations, or product presentations might eventually be reviewed by regulators
  • Long-term cardiovascular and kidney outcomes

Plain-English takeaway

Retatrutide is promising research, not an approved treatment. Phase 3 results and regulatory review—not online availability or early headlines—will determine what claims are supported.

Research and reference links

Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.

  1. 1
    ClinicalTrials.gov: TRIUMPH-5 Phase 3 study

    Registered Phase 3 comparison of retatrutide and tirzepatide in adults with obesity.

  2. 2
    ClinicalTrials.gov: TRIUMPH-Outcomes

    Registered cardiovascular and kidney outcomes trial.

  3. 3
    PubMed research: retatrutide

    Peer-reviewed literature indexed by the National Library of Medicine.